|
Long-term
results of combined-modality therapy for locally advanced
breast cancer with ipsilateral supraclavicular metastases:
The University of Texas M.D. Anderson Cancer Center experience.
Brito
RA, Valero V, Buzdar AU, et al. Journal
of Clinical Oncology. 19(3):628-633, 2001 Feb 1.
Intraarterial
infusion chemotherapy and radiotherapy with or without surgery
for patients with locally advanced or recurrent breast cancer.
Murakami
M, Kuroda Y, Nishimura S, et al. Am
J Clin Oncol. 2001;24:185-91.
Absence
of endothelial cells, central necrosis, and fibrosis are associated
with aggressive inflammatory breast cancer.
Shirakawa K, Tsuda H, Heike Y, et al. Cancer Research. 61(2):445-451,
2001 Jan 15.
Inflammatory
breast cancer survival: the role of obesity and menopausal
status at diagnosis.
Chang S, Alderfer JR, Asmar L, Buzdar AU. Breast Cancer Res
Treat. 2001;64:157-63.
Locoregionally
recurrent breast cancer: incidence, risk factors and survival.
Clemons M, Danson S, Hamilton T, Goss P. Cancer Treat Rev.
2001;27:67-82.
Does
treatment at the time of locoregional failure of breast cancer
alter prognosis?
Clemons M, Hamilton T, Goss P. Cancer Treat Rev. 2001;27:83-97.
Influence
of TP53 gene alterations and c-erbB-2 expression on the response
to treatment with doxorubicin in locally advanced breast cancer.
Geisler S, Lonning PE, Aas T, et al. Cancer Res. 2001;61:2505-12.
Preoperative
hormone therapy trials for breast cancer [Review].
Cheung KL, Robertson JFR. Breast. 10(1):1-5, 2001 Feb.
Adjuvant
and neoadjuvant treatment of breast cancer [Review].
Gianni L, Valagussa P, Zambetti M, Moliterni A, Capri G, Bonadonna
G. Seminars in Oncology. 28(1):13-29, 2001 Feb.
|
